AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04274075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Capsule, Fasted: Treatment B
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Study NCT04274075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Capsule, Fed: Treatment C
Description: One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
Study NCT02699827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine hydrochloride
Description: Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
Study NCT02699827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine hydrochloride
Description: Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
Study NCT02699827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Patients will receive epidural 5 ml magnesium sulphate 10%
Study NCT02699827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Patients will receive epidural 5 ml saline 0.9%
Study NCT04264754 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood will be collected via routine venipuncture procedure
Study NCT01238419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiotulle
Description: Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
Study NCT01238419 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: URGOTUL
Description: Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
Study NCT03776526 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fitbit® Alta HR Sleep monitoring
Description: Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
Study NCT04414423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow concentrate alveolar cleft grafting
Description: patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
Study NCT04414423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous alveolar grafting
Description: patients will undergo surgery to repair alveolar cleft with autogenous bone graft
Study NCT02169297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Sub-Paraspinal Block
Description: Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
Study NCT02169297 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA only
Description: Patients received intravenous PCA post-operatively
Study NCT02169297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA only
Description: Patients received intravenous PCA post-operatively
Study NCT04305860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified starch without flavoring
Description: Each patient of this group receives the thickener during three days of hospitalization
Study NCT04305860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mofidied starch with Bi1 aromas
Description: Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
Study NCT04305860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xanthan gum without flavoring
Description: Each patient of this group receives the thickener during three days of hospitalization
Study NCT04305860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xanthan gum with Bi1 aromas
Description: Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
Study NCT02469233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
Study NCT02469233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
Study NCT03184571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib; pembrolizumab
Description: Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
Study NCT00645671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Loteprednol Etabonate Ophthalmic Ointment
Description: 1/2 inch ribbon four times a day for 14 days
Study NCT00645671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Loteprednol Etabonate Ophthalmic Ointment
Description: 1/2 inch ribbon four times a day for 14 days
Study NCT02693717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02693717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT03675529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training bout
Description: Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
Study NCT03117361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Description: Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
Study NCT03117361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
Study NCT03117361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
Study NCT03639129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography
Description: Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
Study NCT03639129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Standard of care
Study NCT02359279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium iodide
Description: Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MRI at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro-Encephalography-High Density (children with unilateral PC only)
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-Encephalography-High Density (children with unilateral PC only)
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
Study NCT04017871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
Study NCT04017871 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accelerometers
Description: During 5 days a sensor at each wrist to quantify their movement.
Study NCT04017871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometers
Description: During 5 days a sensor at each wrist to quantify their movement.
Study NCT02296762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study NCT02296762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study NCT04412798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: orange juice concentrate
Description: 250mL of 100% orange juice made from concentrate
Study NCT04412798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sugar-sweetened orange-flavoured beverage
Description: Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
Study NCT04412798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole orange juice with skin removed
Description: Whole orange pieces with skin removed, energy-matched to the orange juice condition
Study NCT00680615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored, enhanced condition
Description: Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
Study NCT00680615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
Study NCT03758235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 UNT Injection [Xeomin]
Description: Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Study NCT03758235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Study NCT02479113 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
Study NCT00836446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Description: physical activity routines 5 times a weeks for 12 weeks.
Study NCT00836446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity routines 5 times a weeks for 12 weeks.
Study NCT01745614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Reference product
Study NCT01745614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Test product
Study NCT03653312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Neuromuscular electrical stimulation of the paretic lower limb during exercise
Study NCT00809094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Study NCT00809094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01017081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
Study NCT01017081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and cough
Description: Non-mandatory request to maintain lateral positioning to improve air exchange and cough
Study NCT03181685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 25 MG subcutaneous
Description: A single subcutaneous administration per day from the day of oocyte retrieval
Study NCT03181685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone 200 MG
Description: 3 vaginal administrations per day from the day of oocyte retrieval
Study NCT03181685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: Controlled ovarian stimulation (COS)
Study NCT03181685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix Acetate
Description: Inhibition of Luteinizing Hormone (LH) premature surge during COS
Study NCT01427270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone controlled-release
Description: Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
Study NCT01427270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl controlled-release
Description: Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Study NCT01427270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study NCT03591224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic Testing
Description: pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
Study NCT03591224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacist Standard of Care
Description: Pharmacist providing standard of care as per usual practice
Study NCT04202965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Active treatment with PTG-300 injected subcutaneously.
Study NCT00272844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crystalline cholesterol oil-based suspension
Description: 200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
Study NCT03326115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Visitation Program
Description: The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
Study NCT00933985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00933985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00933985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study NCT00933985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV
Study NCT00933985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00933985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00502099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2a
Description: Injections: 180 ug once per week
Study NCT00502099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablets, 1000-1200 daily
Study NCT00502099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2 b plus ribavirin
Description: Pegylated interferon alpha 2 b injections
Study NCT04470479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Hydrochloride
Description: Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
Study NCT02472340 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Muscle Biopsy
Study NCT03471858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical balloon
Description: To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
Study NCT04470479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03058471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
Study NCT03471858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandins
Description: Prostin will be used in the control arm.
Study NCT03058471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: this arm will be given NSAID to the tolerable full dose with pantoprazole
Study NCT03058471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
Study NCT02694367 — intervention group
Intervention type: OTHER
Intervention: Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins
Study NCT02885584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation
Study NCT00822770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I
Study NCT01651754 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal influenza vaccination
Description: single dose of influenza vaccination
Study NCT02237989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1500 mg
Study NCT02237989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol+native collagen type 2
Description: paracetamol (1500 mg) + native collagen type 2 (10mg)
Study NCT04040647 — intervention group
Intervention type: BEHAVIORAL
Intervention: mobilization and ambulation
Description: 6-min walk test (6-MWT)
Study NCT03900572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: Intramuscular injection, 3 doses
Study NCT03900572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 3 doses
Study NCT03665077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial blood draw
Description: At baseline, patients will undergo a blood draw.
Study NCT03821220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized physical activity prescription
Description: Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.